Amolyt hauls in €130M round to fund PhI­II tri­al of hy­poparathy­roidism drug

French-Amer­i­can biotech Amolyt Phar­ma has raised a €130 mil­lion ($138 mil­lion) Se­ries C round, plan­ning to use the cash to take its hy­poparathy­roidism drug in­to fi­nal-stage test­ing and move an­oth­er ex­per­i­men­tal drug in­to the clin­ic.

The fundraise, which was led by VC firm Sofinno­va Part­ners, comes less than a year and a half af­ter the com­pa­ny’s $80 mil­lion Se­ries B.

Last year, the com­pa­ny re­leased da­ta for the hy­poparathy­roidism drug, AZP-3601, show­ing that 93% of pa­tients in a Phase IIa tri­al were able to dis­con­tin­ue the use of ex­ist­ing drugs. Pa­tients with the dis­ease pro­duce too lit­tle parathy­roid hor­mone, which can throw off the bal­ance of cal­ci­um and phos­pho­rus in the body. That can lead to twitch­ing, fa­tigue, burn­ing sen­sa­tions and oth­er symp­toms.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER